Advancing Next-Generation Delivery, Gene Editing, & Assay Development to Optimize the Clinical Impact, Risk–Benefit Profile, & Scalability of Gene Therapies
Gene therapy is entering a defining new chapter. After a period of challenge and recalibration, the field is regaining momentum, driven by teams who remain steadfast in their belief that this science can transform lives. Confidence is returning, with significant investments and acquisitions signalling a renewed commitment to overcoming barriers of safety, efficacy, and scalability.
The 9th Gene Therapy Development Summit returns to Boston as the meeting point for this community. Join 100+ leading voices from the likes of Bayer, Astellas Pharmaceuticals, REGENXBIO, Ocugen, AskBio, CureDuchenne Ventures, and more to come together to share ideas, restore confidence, and chart a sustainable path forward for gene therapy.
Connect with your peers in pre-clinical development, manufacturing, analytical development, clinical operations, and regulatory affairs for an unrivalled learning and networking opportunity across the end-to-end of gene therapy development.
Attending Companies Include